Kite Pharma released the news on Rare Diseases Day promising top-line data from a Phase 1/2 trial of its treatment for various types of non-Hodgkin lymphoma. The results displayed that approximately a third of patients had experienced a complete response, with all signs of cancer removed from the body, after six months of treatment.
↧
Kite Pharma climbs on strong data showing in lymphoma trial
↧